%0 Journal Article
%A Sharma, Rohini
%A Alharbi, Sultan N
%A Ellum, Ksenia
%A Motedayen-Aval, Leila
%A Casadei-Gardini, Andrea
%A Pinato, David J
%A Bettinger, Dominik
%A Bengsch, Bertram
%A Patel, Rishi
%A Evans, Joanne
%T Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma.
%J npj precision oncology
%V 9
%N 1
%@ 2397-768X
%C [London]
%I Springer Nature
%M DKFZ-2025-01336
%P 214
%D 2025
%X Survival following transarterial chemoembolisation (TACE) for hepatocellular cancer (HCC) is variable. We explored targeted sequencing of circulating tumour DNA (ctDNA) as a prognostic biomarker. Plasma samples (n = 97) were collected at baseline and following TACE. Targeted, ultra-deep sequencing was conducted on 18 somatic mutations related to the molecular pathogenesis of HCC. Median progression-free survival and overall survival were 11.6 months (95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40596669
%2 pmc:PMC12218101
%R 10.1038/s41698-025-00961-2
%U https://inrepo02.dkfz.de/record/302796